A drug development platform for immunogenicity and toxicity assessment using advanced multi-omic profiling
Manon Scholaert1,2, Mathias Peries2, Emilie Braun2, Alexandra Ochando3, Emeline Pagès2 and Nicolas Gaudenzio1,2
1Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France, 2Genoskin SAS, Toulouse, France, 3Genoskin Inc, Salem MA, USA
Longitudinal maintenance of human skin viability in HypoSkin®
At the conference, Genoskin presented data demonstrating the longitudinal maintenance and viability of human skin in the HypoSkin® platform, supporting its application for immunogenicity and toxicity assessment in drug development.
The poster highlighted how the platform enables characterization of immune and tissue responses over time using advanced multi-omic and spatial profiling approaches. The data further illustrated the ability of ex vivo human skin models to preserve native tissue architecture and immune competency, supporting more translationally relevant evaluation of drug-induced responses in a human-based system.
Please fill in the form below to access the full poster.
After submitting this form, you will receive an email with the link to access our poster.
Want more research like this in your inbox? Subscribe to our newsletter →
Comments are closed.